Immune effector cell-associated neurotoxicity syndrome following CAR T-cell therapy: a review of recent advances
Open Access
- 26 December 2025
- journal article
- review article
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Abstract
Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment landscape for hematologic malignancies. However, immune effector cell-associatKeywords
This publication has 77 references indexed in Scilit:
- CAR-T cells containing CD28 versus 4-1BB co-stimulatory domains show distinct metabolic profiles in patientsCell Reports, 2025
- Correction of Electrolyte Abnormalities in Critically Ill PatientsIntensive Care Research, 2024
- An update on ICU outcomes in patients after CAR T therapy: A four-year tertiary UK centre experienceJournal of Critical Care, 2023
- Base Editing and Prime Editing: Potential Therapeutic Options for Rare and Common DiseasesBioDrugs, 2023
- CAR t-cell therapy in BOlogNa–NEUrotoxicity TReatment and Assessment in Lymphoma (CARBON–NEUTRAL): proposed protocol and results from an Italian studyJournal of Neurology, 2023
- CAR-T Cell Therapy: the Efficacy and Toxicity BalanceCurrent Hematologic Malignancy Reports, 2023
- The Economic Burden of CAR T Cell Therapies Ciltacabtagene Autoleucel and Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the USBioDrugs, 2022
- Mechanisms of immune effector cell‐associated neurotoxicity syndrome after CAR‐T treatmentWIREs Mechanisms of Disease, 2022
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector CellsTransplantation and Cellular Therapy, 2019
- Manufacturing chimeric antigen receptor T cells: issues and challengesCytotherapy, 2019